Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Multicenter, Open-label, Single Arm Clinical Study of Pomalidomide and dexamethasonE in RelapSed Myeloma Plus rEsponse Adapted Cyclophosphamide as a Tailored InnoVativE Strategy

NCT02046915 is registered in ClinicalTrials.gov with University Hospital Tuebingen as lead sponsor.

NCT NCT02046915
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02046915 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Multicenter, Open-label, Single Arm Clinical Study of Pomalidomide and dexamethasonE in RelapSed Myeloma Plus rEsponse Adapted Cyclophosphamide as a Tailored InnoVativE Strategy
Lead sponsor
University Hospital Tuebingen
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2014
Completion date
August 17, 2017
Enrollment
60 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed or refractory multiple myeloma